A closer look / pause points
Which offers deserve a pause?
You do not need to decode a whole sales page. Start with the claims that can be checked.
Does “research only” make it treatment?
In warning letters available by September 28, 2026, FDA, the US drug agency, accused sellers of offering cagrilintide as medicine for people despite “research only” labels. The products were unapproved.
FDA’s accusations concerned the sellers named in those letters. They were not court decisions about every offer.
A research label and a clinical trial are different things. Ask for the registered study record if someone says an offer is part of research.
Open the source note
A “research only” label does not make a product an approved medicine for people.
Does a drug code prove approval?
In September 2026, FDA said an NDC, short for National Drug Code, did not prove that it had approved the product.
Ask for the approved product name. A code, a certificate or the word “registered” does not answer that question.
Open the source note
The directory is a listing system, rather than an approval decision.
Can “pharmacy-made” mean the same product?
Compounding means a pharmacy mixes or makes a medicine for a patient. As of September 2026, those pharmacy-made products did not have FDA approval.
For cagrilintide specifically, FDA said federal law does not permit compounding it.
A low advertised price does not show that a medicine is approved. Ask about the name, the source and the full bill.
Open the source note
Compounding can meet some patient needs; that does not remove the cagrilintide-specific limit.
What if the page promises dramatic results?
The FTC, the US consumer protection agency, warns that health adverts can use false endorsements and unsupported cure claims.
Check which drug the study used and which people were in it. A bold result needs that context.
Open the source note
An advert is a claim to examine, rather than evidence by itself.